癌症筛查结果异常后需要及时跟进，以最大限度地发挥筛查的效益，但往往无法实现。我们对患者在异常筛查结果跟踪过程中的经历知之甚少。评估患者对异常乳腺癌、宫颈癌或结直肠癌筛查结果后的诊断检查过程的经历和看法。对 2021 年 4 月至 2022 年 6 月期间参与患者的调查在一项随机对照试验中达到主要结果时间点后，以改善逾期异常筛查结果的随访。来自三个初级保健实践网络 44 个参与实践的患者。自我报告安排随访的难易程度、感知到的障碍或担忧，总体而言，241 名患者 (25.0%) 完成了调查，其中 66 名患者 (32.8%) 患有乳腺癌，79 名患者 (25.3%) 患有宫颈癌，96 名患者患有宫颈癌(21.3%)进行结直肠筛查测试；中位年龄 55 岁，79.7% 为女性，80.5% 非西班牙裔白人，51.0% 未完成建议的随访。大多数患者担心测试会发现癌症（63.1%），但较少担心不适或副作用（34.4%），而且两者都与完成随访无关。然而，17% 的患者认为他们不需要随访检查或预约，并且不太可能完成随访（分别为 10.5% 和 24.0%，p 值 0.009）。大多数患者对他们的整体护理非常满意（71.0%），但只有 50.2% 强烈同意他们相信他们的医疗服务提供者在提出建议时将他们的医疗需求放在第一位。 逾期异常乳腺癌、宫颈癌和结直肠癌筛查测试的患者结果报告了建议的后续行动管理方面的重大缺陷。解决患者对癌症恐惧的担忧并有效传达后续程序的需要，可以改善癌症筛查结果异常后的及时随访。ClinicalTrials.gov NCT03979495.© 2024。作者获得美国癌症学会的独家许可一般内科。

Timely follow-up after an abnormal cancer screening test result is needed to maximize the benefits of screening, but is frequently not achieved. Little is known about patient experiences with the process of following up abnormal screening results.Assess patient experiences and perceptions regarding the process of a diagnostic workup following abnormal breast, cervical, or colorectal cancer screening results.Survey of participating patients between April 2021 and June 2022 after reaching the primary outcome time point in a randomized controlled trial to improve follow-up of overdue abnormal screening results.Patients from 44 participating practices in three primary care practice networks.Self-reported ease of scheduling follow-up, perceived barriers or concerns, provider trust, and satisfaction with communication and care received for the follow-up of abnormal screening results.Overall, 241 (25.0%) patients completed the survey including 66 (32.8%) with breast, 79 (25.3%) with cervical, and 96 (21.3%) with colorectal screening test; median age 55 years, 79.7% women, 80.5% non-Hispanic white, and 51.0% did not complete recommended follow-up. Most patients were worried that the test would find cancer (63.1%), but fewer worried about discomfort or side effects (34.4%), and neither were associated with completing follow-up. However, 17% of patients did not think they needed follow-up tests or appointments and were less likely to complete follow-up (10.5% vs. 24.0%, respectively, p-value 0.009). Most patients were very satisfied with their overall care (71.0%), but only 50.2% strongly agreed that they trusted their provider to put their medical needs above all else when making recommendations.Patients with overdue abnormal breast, cervical, and colorectal cancer screening test results reported important deficiencies in the management of recommended follow-up. Addressing patient concerns about fear of cancer and effectively communicating the need for follow-up procedures may improve timely follow-up after an abnormal cancer screening result.ClinicalTrials.gov NCT03979495.© 2024. The Author(s), under exclusive licence to Society of General Internal Medicine.